In the Chinese pharmaceutical market, Budesonide mainly has three dosage forms, including inhalation suspension, gas (powder) aerosol, and nasal spray. The most common one is Budesonide inhalation suspension, which was first developed and produced by AstraZeneca. In 2001, Budesonide entered the Chinese market. By 2020, the main manufacturers of Budesonide in China are AstraZeneca, Chia Tai Tianqing, Synmosa Biopharma, and Lunan.

According to CRI market research, the sales of Budesonide increased from 2016 to 2019, with a CAGR of approximately 9.26%. However, the sales of Budesonide decreased by 29.30% in 2020 because of the COVID-19 epidemic. The sales revenue in 2020 was approximately CNY1.1 billion. With the improvement of the epidemic situation, CRI predicts that the sales of Budesonide in China will have a recovery growth in the short run.

In recent years, the respiratory sector in the Chinese pharmaceutical market has a growth trend, mainly due to the heavy burden of asthma patients, the high smoking rate, and the deepening of aging. Thus, CRI analyzes that in addition to the recovery growth, the sales of Budesonide will increase in 2021-2025 as the market expands.

Topics Covered:
-The impact of COVID-19 on China’s budesonide market
– Sales value and volume of China’s budesonide 2016-2020
– Competitive landscape of China’s budesonide market
– Prices of budesonide in China
– Prices of budesonide in China by regions and manufacturers
– Analysis on factors affecting the development of China’s budesonide market
– Prospect of China’s budesonide market from 2021 to 2025

The post Investigation Report on Chinese Budesonide Market 2021-2025 first appeared on CRI Report.